Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

New study extends our knowledge of the link between miRNAs and cancer

The abnormal expression of different classes of molecules is known to be linked to various types of cells becoming cancerous.

21 Jan 2019

Researchers discover mechanism which drives leukemia cell growth

A mechanism which drives leukemia cell growth has been discovered by researchers at the University of Sussex, who believe their findings could help to inform new strategies when it comes to treating cancer.

17 Jan 2019

Scientists discover two therapies that slow progression of pediatric leukemia in mice

Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.

24 Dec 2018

Active ingredient in eye drops shows promise for treating aggressive blood cancer

An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukemia cells without harming non-leukemic blood cells.

19 Dec 2018

Research advances offer hope for patient-tailored AML treatment

Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia.

10 Dec 2018

Research highlights ability of Bio-Rad's ddPCR in quantifying minimal residual disease

More than 30 abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, December 1-4, featured research highlighting the ability of Bio-Rad's Droplet Digital PCR to provide high sensitivity and accuracy in quantifying minimal residual disease -- those remaining cancer cells after therapy that are associated with relapse -- in blood diseases such as leukemia.

3 Dec 2018

Cleveland Clinic expert develops personalized prediction model for Myelodysplastic Syndromes

At the American Society of Hematology Annual Meeting, Cleveland Clinic medical hematologist and oncologist Aziz Nazha, M.D., will present results of a personalized prediction model that surpassed current prediction models for Myelodysplastic Syndromes.

3 Dec 2018

FDA approves new combination therapy for acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.

30 Nov 2018

DNA mutations in healthy and leukemic blood stem cells do not differ, shows research

Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

29 Nov 2018

Researchers identify powerful inhibitor of epigenetic factors that promote acute myeloid leukemia

Some severe forms of leukemia develop because proteins on the epigenetic level lose their regulative function. Now, in a broad international collaboration, UK researchers have identified molecules that can effectively inhibit the dysregulated proteins.

27 Nov 2018

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018

St. Jude Hospital announces availability of largest collections of leukemia samples

St. Jude Children's Research Hospital today announced the availability of one of the world's largest collections of leukemia samples from children and adults.

15 Nov 2018

Researchers unravel mystery of NPM1 protein in acute myeloid leukemia

While it has long been recognized that mutated gene NPM1 plays an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

13 Nov 2018

Cancer stem cells depend on amino acid metabolism, and it's proving to be their Achilles' heel

Think of energy metabolism like a party popper: Ripping something apart releases a bang. Most of your cells rip apart sugar to release the "bang" of energy. Sometimes they rip apart fats, and in a pinch, cells can even metabolize protein.

13 Nov 2018

Researchers develop first chemical inhibitors for treatment of acute myeloid leukemia

A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong, in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia, a fast-growing cancer of bone marrow and blood cells.

7 Nov 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Two-cells-in-one combo therapy shows promise in strengthening leukemia treatment

A cancer therapy based on fusing two types of cells into a single unit shows promise in strengthening existing treatments for acute myeloid leukemia. The approach joins blood platelets that carry cancer drugs with stem cells that guide the platelets into bone marrow where leukemia begins.

31 Oct 2018

Scientists identify new target for battling deadly form of leukemia

UT Southwestern scientists, working with colleagues at a sister institution in Houston, have identified a new target for battling a deadly form of leukemia.

24 Oct 2018

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia and a diagnostic test to determine which AML patients would most likely benefit from this treatment.

22 Oct 2018